NKGen Biotech, Inc.

NKGen Biotech, Inc., operating under Nasdaq ticker GFOR, is a clinical-stage biotechnology company focused on natural killer cell-based immunotherapy. The entity traces its public-markets history to Graf Acquisition Corp. IV, a blank-check company sponsored by Graf Acquisition LLC and led by James Graf, which completed its IPO in 2021 targeting the healthcare and life-sciences sector. NKGen Biotech filed this Form 10-Q with the SEC on May 16, 2022, providing a quarterly operational and financial update during the de-SPAC process. The company's pipeline centers on allogeneic NK cell therapies for oncology and neurodegenerative disease indications. Sign up at SpacDesk for the full filing history, sponsor profiles, and deal-timeline data on GFOR and hundreds of other SPAC transactions.